Synthesis and Antitumor Activity Evaluation of Novel Pyrimidoquinoline Derivatives

References

• S. Jain, V. Chandra, P. Kumar Jain, K. Pathak, D. Pathak, and A. Vaidya, “Comprehensive Review on Current Developments of Quinoline-Based Anticancer Agents,” Arabian Journal of Chemistry 12, no. 8 (2019): 4920–46.
   Web of Science ®Google Scholar
• Aram Faraji, Rasoul Motahari, Zaman Hasanvand, Tayebeh Oghabi Bakhshaiesh, Mahsa Toolabi, Setareh Moghimi, Loghman Firoozpour, Mohammad Amin Boshagh, Roya Rahmani, Shima H. M. E. Ketabforoosh, et al. “Quinazolin-4(3H)-One Based Agents Bearing Thiadiazole-Urea: Synthesis and Evaluation of anti-Proliferative and Antiangiogenic Activity,” Bioorganic Chemistry 4 (2020): 104553.
   Google Scholar
• Yuan-Qiang Hu, Chuan Gao, Shu Zhang, Lei Xu, Zhi Xu, Lian-Shun Feng, Xiang Wu, and Feng Zhao, “Quinoline Hybrids and Their Antiplasmodial and Antimalarial Activities,” European Journal of Medicinal Chemistry 139 (2017): 22–47.
   PubMed Web of Science ®Google Scholar
• G. S. Bisacchi, “Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story” Miniperspective,” Journal of Medicinal Chemistry 58, no. 12 (2015): 4874–82.
   PubMed Web of Science ®Google Scholar
• H. A. S. Abbas, H. N. Hafez, and A. R. B. A. El-Gazzar, “Synthesis, in Vitro Antimicrobial and in Vivo Antitumor Evaluation of Novel Pyrimidoquinolines and Its Nucleoside Derivatives,” European Journal of Medicinal Chemistry 46, no. 1 (2011): 21–30.
   PubMed Web of Science ®Google Scholar
• A. H. Kategaonkar, R. U. Pokalwar, S. S. Sonar, V. U. Gawali, B. B. Shingate, and M. S. Shingare, “Synthesis, in Vitro Antibacterial and Antifungal Evaluations of New Alpha-hydroxyphosphonate and New Alpha-acetoxyphosphonate Derivatives of Tetrazolo [1, 5-a] Quinoline,” European Journal of Medicinal Chemistry 45, no. 3 (2010): 1128–32.
   PubMed Web of Science ®Google Scholar
• Muhammad Taha, Sadia Sultan, Syahrul Imran, Fazal Rahim, Khalid Zaman, Abdul Wadood, Ashfaq Ur Rehman, Nizam Uddin, and Khalid Mohammed Khan, “Synthesis of Quinoline Derivatives as Diabetic II Inhibitors and Molecular Docking Studies,” Bioorganic & Medicinal Chemistry 27, no. 18 (2019): 4081–8.
   PubMed Web of Science ®Google Scholar
• S. Mukherjee and M. Pal, “Medicinal Chemistry of Quinolines as Emerging anti-Inflammatory Agents: An Overview,” Current Medicinal Chemistry 20, no. 35 (2013): 4386–410.
   PubMed Web of Science ®Google Scholar
• S. E. Adeniji, G. Adamu Shallangwa, D. Ebuka Arthur, M. Abdullahi, A. Y. Mahmoud, and A. Haruna, “Quantum Modelling and Molecular Docking Evaluation of Some Selected Quinoline Derivatives as anti-Tubercular Agents,” Heliyon 6, no. 3 (2020): e03639. [32258484]
   PubMed Web of Science ®Google Scholar
• A. A. Aly, A. H. Mohamed, and M. Ramadan, “Synthesis and Colon Anticancer Activity of Some Novel Thiazole/-2-Quinolone Derivatives,” Journal of Molecular Structure 1207 (2020): 127798.
   Web of Science ®Google Scholar
• M. M. Ghorab, F. A. Ragab, H. I. Heiba, Y. M. Nissan, and W. M. Ghorab, “Novel Brominated Quinoline and Pyrimidoquinoline Derivatives as Potential Cytotoxic Agents with Synergistic Effects of γ-Radiation,” Archives of Pharmacal Research 35, no. 8 (2012): 1335–46.
   PubMed Web of Science ®Google Scholar
• M. B. El-Ashmawy, M. A. El-Sherbeny, and N. S. El-Gohary, “Synthesis and Antitumor Screening of New Series of Pyrimido-[4,5-B] Quinolines and [1,2,4]Triazolo[2′,3′:3,4]Pyrimido[6,5-B]Quinolines,” Medicinal Chemistry Research 22, no. 6 (2013): 2724–36.
   Web of Science ®Google Scholar
• S. I. Alqasoumi, A. M. Al-Taweel, A. M. Alafeefy, E. Noaman, and M. M. Ghorab, “Novel Quinolines and Pyrimido[4,5-B]Quinolines Bearing Biologically Active Sulfonamide Moiety as a New Class of Antitumor Agents,” European Journal of Medicinal Chemistry 45, no. 2 (2010): 738–44.
   PubMed Web of Science ®Google Scholar
• C. C. Bernal, L. C. Vesga, S. C. Mendez-Sánchez, and A. R. Romero Bohórquez, “Synthesis and Anticancer Activity of New Tetrahydroquinoline Hybrid Derivatives Tethered to Isoxazoline Moiety,” Medicinal Chemistry Research 29, no. 4 (2020): 675–89.
   Web of Science ®Google Scholar
• M. Abass, A. R. A. Alzandi, M. M. Hassan, and N. Mohamed, “Recent Advances on Diversity Oriented Heterocycle Synthesis of Fused Quinolines and Its Biological Evaluation,” Polycyclic Aromatic Compounds 0 (2020): 1–90.
   Google Scholar
• Lhassane Ismaili, Arulraj Nadaradjane, Laurence Nicod, Catherine Guyon, Alain Xicluna, Jean-François Robert, and Bernard Refouvelet, “Synthesis and Antioxidant Activity Evaluation of New Hexahydropyrimido[5,4-C]Quinoline-2,5-Diones and 2-Thioxohexahydropyrimido[5,4-C]Quinoline-5-Ones Obtained by Biginelli Reaction in Two Steps,” European Journal of Medicinal Chemistry 43, no. 6 (2008): 1270–5.
   PubMed Web of Science ®Google Scholar
• A. B. A. El-Gazzar, H. N. Hafez, A. A. Abu-Hashem, and A. S. Aly, “Synthesis and Antioxidant, anti-Inflammatory, and Analgesic Activity of Novel Polycyclic Pyrimido[4,5-B]Quinolines,” Phosphorus, Sulfur and Silicon and the Related Elements 184, no. 2 (2009): 379–405.
   Web of Science ®Google Scholar
• Reza Araghi, Bi Bi Fatemeh Mirjalili, Leila Zamani, Soghra Khabnadideh, Kamiar Zomoridian, Zeinab Faghih, and Hamidreza Arabi, “Docking, Synthesis and Evaluation of the Antifungal Activity of Pyrimido [4,5-b]quinolines ,” Iranian Journal of Pharmaceutical Research: IJPR 19, no. 1 (2020): 251–9.
   PubMed Web of Science ®Google Scholar
• S. Ranjbar, N. Edraki, O. Firuzi, M. Khoshneviszadeh, and R. Miri, “5-Oxo-Hexahydroquinoline: An Attractive Scaffold with Diverse Biological Activities,” Molecular Diversity 23, no. 2 (2019): 471–508.
   PubMed Web of Science ®Google Scholar
• A. Ayati, S. Moghimi, S. Salarinejad, M. Safavi, B. Pouramiri, and A. Foroumadi, “A Review on Progression of Epidermal Growth Factor Receptor (EGFR) Inhibitors as an Efficient Approach in Cancer Targeted Therapy,” Bioorganic Chemistry 99 (2020): 103811.
   PubMed Web of Science ®Google Scholar
• Mahsa Toolabi, Setareh Moghimi, Tayebeh Oghabi Bakhshaiesh, Somayeh Salarinejad, Ayoub Aghcheli, Zaman Hasanvand, Elahe Nazeri, Ali Khalaj, Rezvan Esmaeili, Alireza Foroumadi, et al. “6-Cinnamoyl-4-Arylaminothienopyrimidines as Highly Potent Cytotoxic Agents: Design, Synthesis and Structure-Activity Relationship Studies,” European Journal of Medicinal Chemistry 185 (2020): 111786.
   PubMed Web of Science ®Google Scholar
• S. A. El-Assiery, G. H. Sayed, and A. Fouda, “Synthesis of Some New Annulated Pyrazolo-Pyrido (or Pyrano) Pyrimidine,” Acta Pharmaceutica (Zagreb, Croatia) 54 (2004): 143–50.
   PubMedGoogle Scholar
• M. M. Ghorab, M. A. Shaaban, H. M. Refaat, H. I. Heiba, and S. S. Ibrahim, “Anticancer and Radiosensitizing Evaluation of Some New Pyranothiazole-Schiff Bases Bearing the Biologically Active Sulfonamide Moiety,” European Journal of Medicinal Chemistry 53 (2012): 403–7.
   PubMed Web of Science ®Google Scholar
• F. Safari, H. Hosseini, M. Bayat, and A. Ranjbar, “Synthesis and Evaluation of Antimicrobial Activity, Cytotoxic and Pro-Apoptotic Effects of Novel Spiro-4 H -Pyran Derivatives,” RSC Advances 9, no. 43 (2019): 24843–51.
   PubMed Web of Science ®Google Scholar
• X. Liu, P. Li, P. Widlak, H. Zou, X. Luo, W. T. Garrard, and X. Wang, “The 40-KDa Subunit of DNA Fragmentation Factor Induces DNA Fragmentation and Chromatin Condensation during Apoptosis,” Proceedings of the National Academy of Sciences of the United States of America 95, no. 15 (1998): 8461–6.
   PubMed Web of Science ®Google Scholar
• R. Gerl and D. L. Vaux, “Apoptosis in the Development and Treatment of Cancer,” Carcinogenesis 26, no. 2 (2005): 263–70.
   PubMed Web of Science ®Google Scholar
• R. S. Y. Wong, “Apoptosis in Cancer: From Pathogenesis to Treatment,” Journal of Experimental & Clinical Cancer Research: CR 30 (2011): 87.
   PubMed Web of Science ®Google Scholar